Travis Alvin Thompson Sells 2,686 Shares of Bicycle Therapeutics plc (NASDAQ:BCYC) Stock

Bicycle Therapeutics plc (NASDAQ:BCYC) CAO Travis Alvin Thompson sold 2,686 shares of the stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $15.00, for a total transaction of $40,290.00. Following the transaction, the chief accounting officer now owns 32,146 shares in the company, valued at approximately $482,190. This trade represents a 7.71 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Travis Alvin Thompson also recently made the following trade(s):

• On Thursday, January 2nd, Travis Alvin Thompson sold 1,750 shares of Bicycle Therapeutics stock. The shares were sold at an average price of $14.09, for a total transaction of $24,657.50.
• On Monday, November 11th, Travis Alvin Thompson sold 6,256 shares of Bicycle Therapeutics stock. The stock was sold at an average price of $25.11, for a total value of $157,088.16.

Bicycle Therapeutics Price Performance

Shares of BCYC stock opened at $14.17 on Thursday. Bicycle Therapeutics plc has a one year low of $12.17 and a one year high of $28.67. The company’s fifty day moving average price is $19.09 and its 200-day moving average price is $21.82. The company has a market capitalization of $978.38 million, a price-to-earnings ratio of -4.31 and a beta of 0.92.

Bicycle Therapeutics (NASDAQ:BCYC) last posted its quarterly earnings results on Thursday, October 31st. The company reported ($0.74) EPS for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.04. The business had revenue of $2.68 million for the quarter, compared to analysts’ expectations of $6.82 million. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. The business’s quarterly revenue was down 50.0% on a year-over-year basis. During the same period last year, the firm earned ($1.26) earnings per share. Equities research analysts expect that Bicycle Therapeutics plc will post -3.05 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on BCYC. JMP Securities lowered their target price on Bicycle Therapeutics from $32.00 to $26.00 and set a “market outperform” rating on the stock in a report on Wednesday, December 18th. Needham & Company LLC reiterated a “buy” rating and issued a $38.00 price objective on shares of Bicycle Therapeutics in a research note on Thursday, October 31st. B. Riley cut their target price on shares of Bicycle Therapeutics from $28.00 to $17.00 and set a “neutral” rating for the company in a research report on Friday, December 13th. Stephens assumed coverage on shares of Bicycle Therapeutics in a research report on Friday, November 8th. They issued an “equal weight” rating and a $25.00 price target on the stock. Finally, HC Wainwright cut their price objective on shares of Bicycle Therapeutics from $55.00 to $33.00 and set a “buy” rating for the company in a research report on Monday, December 16th. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $35.25.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Armistice Capital LLC lifted its holdings in shares of Bicycle Therapeutics by 17.9% in the second quarter. Armistice Capital LLC now owns 1,972,000 shares of the company’s stock worth $39,913,000 after buying an additional 300,000 shares in the last quarter. Westfield Capital Management Co. LP lifted its stake in Bicycle Therapeutics by 21.5% in the 3rd quarter. Westfield Capital Management Co. LP now owns 1,850,945 shares of the company’s stock worth $41,887,000 after purchasing an additional 327,089 shares in the last quarter. First Light Asset Management LLC boosted its holdings in shares of Bicycle Therapeutics by 16.1% during the 2nd quarter. First Light Asset Management LLC now owns 1,384,768 shares of the company’s stock valued at $28,028,000 after purchasing an additional 191,717 shares during the last quarter. Point72 Asset Management L.P. grew its position in shares of Bicycle Therapeutics by 1,438.1% during the third quarter. Point72 Asset Management L.P. now owns 899,799 shares of the company’s stock valued at $20,362,000 after purchasing an additional 841,299 shares in the last quarter. Finally, Avoro Capital Advisors LLC bought a new stake in shares of Bicycle Therapeutics in the second quarter worth about $14,168,000. 86.15% of the stock is currently owned by institutional investors.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.